GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenxbio Inc (NAS:RGNX) » Definitions » Price-to-Free-Cash-Flow

Regenxbio (Regenxbio) Price-to-Free-Cash-Flow : N/A (As of Apr. 25, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Regenxbio Price-to-Free-Cash-Flow?

As of today (2024-04-25), Regenxbio's share price is $16.09. Regenxbio's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.23. Hence, Regenxbio's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Regenxbio's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 11 years, Regenxbio's highest Price-to-Free-Cash-Flow Ratio was 439.19. The lowest was 8.34. And the median was 17.41.

RGNX's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.19
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Regenxbio's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.95. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-5.23.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -34.00% per year.

During the past 11 years, Regenxbio's highest 3-Year average Free Cash Flow per Share Growth Rate was 7.20% per year. The lowest was -128.80% per year. And the median was -19.30% per year.


Regenxbio Price-to-Free-Cash-Flow Historical Data

The historical data trend for Regenxbio's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenxbio Price-to-Free-Cash-Flow Chart

Regenxbio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 10.66 - -

Regenxbio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Regenxbio's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Regenxbio's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenxbio's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenxbio's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Regenxbio's Price-to-Free-Cash-Flow falls into.



Regenxbio Price-to-Free-Cash-Flow Calculation

Regenxbio's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=16.09/-5.228
=N/A

Regenxbio's Share Price of today is $16.09.
Regenxbio's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.23.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Regenxbio  (NAS:RGNX) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Regenxbio Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Regenxbio's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenxbio (Regenxbio) Business Description

Traded in Other Exchanges
Address
9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).
Executives
Kenneth T. Mills director, officer: See Remarks C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Vittal Vasista officer: See Remarks C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Jennifer Zachary director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Steve Pakola officer: Chief Medical Officer C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Allan M. Fox director, 10 percent owner C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Jean Bennett director C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
George V Migausky director C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Patrick J. Christmas officer: Senior VP, General Counsel C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Curran Simpson officer: SVP of Technical Operations C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Hayden Donald J Jr director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Olivier Danos officer: Chief Scientific Officer C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Luke M Beshar director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Stephen Yoo officer: Chief Medical Officer C/O REGENXBIO INC,, 9600 BLACKWELL ROAD, SUITE 210, ROCKVILLE MD 20850
Alexandra Glucksmann director C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Daniel Tasse director C/O IKARIA, INC., 6 STATE ROUTE 173, CLINTON NJ 08809